Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
- Resource Type
- Article
- Source
- The Lancet Gastroenterology & Hepatology; February 2024, Vol. 9 Issue: 2 p133-146, 14p
- Subject
- Language
- ISSN
- 24681253